MK-0354 Uses, Dosage, Side Effects and more

MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders. It targets G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of niacin.

Trade Name MK-0354
Generic MK-0354
Type
Formula C7H8N6
Weight Average: 176.183
Monoisotopic: 176.081044282
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: January 7, 2025 at 1:49 am

Uses

Investigated for use/treatment in atherosclerosis.

Innovators Monograph

*** Taking medicines without doctor's advice can cause long-term problems.
Share